DNAbilize Licensing Bio-Path markets DNAbilize, a liposomal antisense delivery platform with broad systemic targeting potential beyond the liver, presenting a licensing opportunity for partnering companies seeking nucleic acid drug delivery capabilities.

Lead Candidate Momentum BP1001 and related liposomal therapies have progressed to Phase II safety segments in AML and CML, signaling ongoing clinical activity and potential near-term value for collaborators in oncology and hematologic malignancies.

Collaborations Open The company explicitly seeks partnerships to develop therapeutics using DNAbilize, offering a structured collaboration approach for drug development projects with external biotech or pharma partners.

Financial and Scale With funding around 57 million and modest revenue, Bio-Path represents a lean, early-stage biotech with potential for value inflection through partnering, licensing deals, or co-development arrangements.

Strategic Roles Recent advisory and board additions indicate active governance and strategic guidance, which can facilitate engagement with potential investors, partners, and large pharma seeking oncology/nucleic acid delivery expertise.